Pharmaceutical stocks rebounded in Thursday morning trading, buoyed by the Federal Reserve’s decision to cut interest rates by 25 basis points. The Nifty Pharma index rose by 138.70 points to reach 22,380.05, reflecting a 0.62 percent increase over its previous close of 22,241.35. The sector experienced widespread buying, with 14 stocks advancing compared to 6 that declined, marking a shift from the profit-booking trend seen on Wednesday.
Natco Pharma topped the performance list, climbing 3.92 percent to ₹890.85, followed closely by Biocon, which increased by 2.27 percent to ₹362.40. Gland Pharma saw a rise of 1.76 percent to ₹2,021.90, and Glenmark Pharmaceuticals gained 1.38 percent, reaching ₹2,070.60. Both Sun Pharma and Aurobindo Pharma contributed positively, with respective increases of 1.04 percent and 0.89 percent.
The Federal Reserve’s dovish stance is anticipated to draw foreign capital into emerging markets, including India, which may strengthen the rupee and benefit stock indices. Rajesh Palviya, Senior Vice President of Research at Axis Securities, commented that the rate cut illustrates a cautious strategy aimed at supporting the labor market and could lead to equity gains across various sectors.
Trading activity within the pharmaceutical sector remained robust, with Biocon leading the volume charts at 49.91 lakh shares traded, equating to a value of ₹180.25 crores. This recovery in the sector follows a Wednesday trading session where profits were taken in metals, FMCG, and pharmaceutical stocks, as noted by market analysts.
Published on September 18, 2025.
